BRA
PTGX icon

Blue Rock Advisors’s Protagonist Therapeutics PTGX Stock Holding History

Blue Rock Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-30,146
Closed -$590K – 75
2020
Q3 		$590K Buy
+30,146
New +$566K 0.51% 67

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Blue Rock Advisors's PTGX Position: Q4 2020 in Review

Blue Rock Advisors sold out of Protagonist Therapeutics (PTGX) in Q4 2020, closing a stake of 30,146 shares — an estimated $590K sold.

Blue Rock Advisors first reported a position in PTGX in Q3 2020 and held it in 1 quarter. The position peaked at $590K in Q3 2020. 128 funds tracked by Wall St. Rank hold PTGX as of Q4 2020.

  • Blue Rock Advisors reported no remaining Protagonist Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Blue Rock Advisors sold 30,146 Protagonist Therapeutics shares in Q4 2020, an estimated $590K.
  • Blue Rock Advisors first reported a position in Protagonist Therapeutics in Q3 2020 and held it in 1 quarter.
  • Blue Rock Advisors's Protagonist Therapeutics position peaked at $590K in Q3 2020.
  • 128 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2020.

Based on Blue Rock Advisors's 13F filing for Q4 2020, filed 12 Feb 2021.